Industries > Pharma > Global Influenza Vaccines Market Outlook 2019-2029

Global Influenza Vaccines Market Outlook 2019-2029

Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other

PUBLISHED: 05 July 2019
PAGES: 155
PRODUCT CODE: PHA0456
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0456 Categories: , Tag:

The latest report from business intelligence provider visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that this market will generate revenues of $3.7 billion in 2019.

How this report will benefit you

In this brand new 155-page report you find 64 in-depth tables, charts and graphs – all unavailable elsewhere.

The report provides clear detailed insight into the global Influenza market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Visiongain’s new investigation shows revenue predictions at overall world market, submarket, company, product and national level.

• This study gives individual analysis for two influenza vaccine submarkets, which are further divided by vaccine technologies:
• Trivalent Influenza Vaccines (TIV)
• Quadrivalent Influenza Vaccines (QIV)

• Our new analysis also shows you revenue predictions for the vaccines produced by these five market leaders: and their market share
• AstraZeneca
• GlaxoSmithKline
• Sanofi Pasteur
• Seqirus
• Others

• Our report analyses the vaccines in research and development and assess their prospects once they enter the market. The R&D pipeline discusses:
• Seasonal Influenza vaccines in development
• Universal Influenza vaccines in development

• The report includes forecasts to 2029 and analysis of pipeline developments for the following specific vaccines:
• Fluzone / VaxiGrip
• Seqirus Influenza Vaccines
• Fluarix / FluLaval
• FluMist / Fluenz
• FluBlok
• Other

Global Influenza Vaccines Market Outlook 2019-2029

• This study shows you forecasts to 2029 of influenza vaccines in developed and developing regions:
• United States
• Japan
• The EU 5 – Germany, France, United Kingdom, Italy and Spain.
• Brazil, Russia, India and China.

• Key Questions Answered by this Report:
• What is the current size of the total global influenza vaccines market? How much will this market be worth from 2019-2029?
• What are the main drivers and restraints that will shape the overall influenza vaccines market over the next ten years?
• What are the main segments within the overall influenza vaccines market? How much will each of these segments be worth for the period 2019-2029? How will the composition of the market change during that time, and why?
• What factors will affect that industry and market over the next ten years?
• What are the largest national markets for influenza vaccines? What is their current status and how will they develop over the next ten years? What are their forecasts for 2019-2029?
• How will political and regulatory factors influence the regional markets?
• How will the market shares of the national markets change by 2029, and which geographical region will lead the market in 2029?
• Who are the leading companies and what are their prospects over the forecast period?
• What are the predictions for existing players and the prospects for new market entrants?
• What are the leading vaccines? What are their revenues and latest developments?
• What are some of the most prominent influenza vaccines currently in development?
• What are the main trends that will affect the influenza vaccines market between 2019 and 2029?
• What are the main strengths, weaknesses, opportunities and threats for the market?
• What are the social, technological, economic and political influences that will shape that industry over the next ten years?
• How will the global influenza vaccines market evolve over the forecasted period, 2019-2029?
Visiongain’s study is intended for anyone requiring commercial analyses for the influenza vaccines market and leading companies. You find data, trends and predictions.

Buy our report today Global Influenza Vaccines Market Outlook 2019-2029: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other. Avoid missing out by staying informed – get our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Influenza Vaccines Market Outlook 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Influenza Vaccines Market Outlook 2019-2029


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category